Page 1275 - Clinical Immunology_ Principles and Practice ( PDFDrive )

CHaPtEr 91 Immunotherapy of Allergic Disease 1235

22. Novembre E, Galli E, Landi F, et al. Coseasonal sublingual 36. Corrigan CJ, Kettner J, Doemer C, et al. Efficacy and safety of
immunotherapy reduces the development of asthma in children with preseasonal-specific immunotherapy with an aluminium-adsorbed
allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851–7. six-grass pollen allergoid. Allergy 2005;60:801–7.
23. Johnstone DE, Dutton A. The value of hyposensitization therapy for 37. Norman PS, Ohman JL, Long AA, et al. Treatment of cat allergy with
bronchial asthma in children. A 14 year study. Pediatrics 1968;42:793–802. T-cell reactive peptides. Am J Respir Crit Care Med 1996;154:1623–8.
24. Di Rienzo V, Marcucci F, Puccinelli P, et al. Long-lasting effect of 38. Wiedermann U, Herz U, Baier K, et al. Intranasal treatment with a
sublingual immunotherapy in children with asthma due to house dust recombinant hypoallergenic derivative of the major birch pollen allergen
mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206–10. Bet v 1 prevents allergic sensitization and airway inflammation in mice.
25. Shaikh WA. Immunotherapy vs inhaled budesonide in bronchial asthma: Int Arch Allergy Immunol 2001;126:68–77.
an open, parallel, comparative trial. Clin Exp Allergy 1997;27:1279–84. 39. Shirakawa T, Enomoto T, Shimazu SI, et al. The inverse association
26. Bernstein DI, Wanner M, Borish L, et al. Twelve-year survey of fatal between tuberculin responses and atopic disorder. Science 1997;275:77–9.
reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin 40. Strannegaard IL, Larsson LO, Wennergren G, et al. Prevalence of allergy
Immunol 2004;113:1129–36. in children in relation to prior BCG vaccination and infection with
27. Frew AJ. Sublingual immunotherapy. N Engl J Med 2008;358:2259–64. atypical mycobacteria. Allergy 1998;53:249–54.
28. Scadding G, Durham SR. Mechanisms of sublingual immunotherapy. 41. Erb KJ, Holloway JW, Sobeck A, et al. Infection of mice with
Immunol Allergy Clin North Am 2011;31:191–209. Mycobacterium bovis-BCG suppresses allergen-induced airways
29. Calderon MA, Penagos M, Sheikh A, et al. Sublingual immunotherapy for eosinophilia. J Exp Med 1998;187:561–9.
allergic conjunctivitis: Cochrane systematic review and meta-analysis. 42. Sur S, Wild JS, Choudury BK, et al. Long-term prevention of allergic lung
Clin Exp Allergy 2011;41:1263–72. inflammation in a mouse model of asthma by CpG
30. de Bot CM, Moed H, Berger MY, et al. Sublingual immunotherapy is not oligodeoxynucleotides. J Immunol 1999;162:6284–93.
effective in house dust mite-allergic children in primary care. Pediatr 43. Marshall JD, Abtahi S, Eiden JJ, et al. Immunostimulatory sequence DNA
Allergy Immunol 2012;23:150–8. linked to the Amb a 1 allergen promotes Th1 cytokine expression while
31. Pauli G, Larsen TH, Rak S, et al. Efficacy of recombinant birch pollen downregulating Th2 cytokine expression in PBMCs from human patients
vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy with ragweed allergy. J Allergy Clin Immunol 2001;108:191–7.
Clin Immunol 2008;122:951–60. 44. Creticos PS, Eiden JJ, Broide D, et al. Immunotherapy with
32. Senti G, Prinz Vavricka BM, Erdmann I, et al. Intralymphatic allergen immunostimulatory oligonucleotides linked to purified ragweed Amb a 1
administration renders specific immunotherapy faster and safer: a allergen: effects on antibody production, nasal allergen provocation and
randomized controlled trial. Proc Natl Acad Sci USA 2008;105:17908–12. ragweed seasonal rhinitis. J Allergy Clin Immunol 2002;109:743–4.
33. Witten M, Malling HJ, Blom L, et al. Is intralymphatic immunotherapy 45. Hartl A, Hochreiter R, Stepanoska T, et al. Characterisation of the
ready for clinical use in patients with grass pollen allergy? J Allergy Clin protective and therapeutic efficiency of a DNA vaccine encoding the
Immunol 2013;132:1248–52. major birch pollen allergen Bet v1a. Allergy 2004;59:65–73.
34. Patterson AM, Bonny AE, Shiels WE, et al. Three-injection intralymphatic 46. Rolinck-Werninghaus C, Hamelmann E, Keil T, et al. The co-seasonal
immunotherapy in adolescents and young adults with grass pollen application of anti-IgE after preseasonal specific immunotherapy
rhinoconjunctivitis. Ann Allergy Asthma Immunol 2016;116:168–70. decreases ocular and nasal symptom scores and rescue medication use in
35. Valenta R, Campana R, Focke-Tejkl M, et al. Vaccine development for grass-pollen allergic children. Allergy 2004;59:973–9.
allergen-specific immunotherapy based on recombinant allergens and
synthetic allergen peptides: Lessons from the past and novel mechanisms
of action for the future. J Allergy Clin Immunol 2016;137:351–7.